Cognizant to apply generative AI to drug discovery with Nvidia BioNeMo

Cognizant (CTSH) is advancing the application of generative AI technology with the Nvidia (NVDA) BioNeMo platform to solve complex challenges of drug discovery in the life sciences industry, such as improving productivity in the development process and increasing the speed at which new, life-saving treatments can be brought to market. By leveraging gen AI technologies, clinical researchers can rapidly sift through extensive datasets, more accurately predict interactions between drug compounds and create new, viable drug development pathways.